Zentalis Q1 2026 cash $211.8M; selects pivotal azenosertib dose; DENALI readout by year-end

Zentalis Pharmaceuticals, Inc.

• Cash, cash equivalents and marketable securities $211.8M as of March 31, 2026; provides runway into late 2027.
• Selected 400mg QD 5:2 as pivotal dose for azenosertib monotherapy in Cyclin E1-positive PROC based on DENALI Part 2a interim.
• DENALI Part 2 topline readout expected by year-end 2026; potential accelerated approval pathway.
• ASPENOVA Phase 3 confirmatory trial in Cyclin E1-positive PROC initiated with first patient dosed.
• Q1 total operating expenses $37.9M, down from $45.6M (includes $7.8M non-recurring restructuring in prior year).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.